We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Companies developing direct-acting antiviral hepatitis C drugs should factor in interferon treatment when designing clinical trials, the FDA said Tuesday. Read More
The House Energy and Commerce Committee is scheduled to mark up a bill Wednesday that would encourage the development of abuse-deterrent opioids. Read More
The FDA is providing updated guidance on assessing the effects of protein-based treatments on the immune system, providing advice on how to validate results but little new information on testing protocols. Read More